PERSPECTIVE article

Front. Pain Res., 11 November 2026

Sec. Veterinary and Comparative Pain

Volume 7 - 2026 | https://doi.org/10.3389/fpain.2026.1999875

Current perspectives: non-rodent models of pain: Pain in Animals Workshop 2025

  • 1. Center for Advanced Pain Studies and Department of Neuroscience, University of Texas at Dallas, Richardson, TX, United States

  • 2. National Institute of Neurological Disorders and Stroke/National Institutes of Health, Bethesda, MD, United States

  • 3. Thurston Arthritis Center, UNC School of Medicine, Chapel Hill, NC, United States

  • 4. Laboratories of Neuroimmunology, Department of Symptom Research, University of Texas MD Anderson Cancer Center, Houston, TX, United States

  • 5. Comparative Behavioral Research, Thinking Pets Program and Comparative Pain Research and Education Center, Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, United States

  • 6. Mars Veterinary Health, Vancouver, WA, United States

  • 7. Department of Anatomy and Physiology, Kansas State University, Manhattan, KS, United States

  • 8. Center for Veterinary Medicine, Food and Drug Administration, College Park, MD, United States

  • 9. Lap of Love Veterinary Hospice, Lutz, FL, United States

  • 10. Translational Research in Pain and Comparative Pain Research and Education Center, Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, United States

  • 11. Center for Translational Pain Research, Department of Anesthesiology, Duke University, Durham, NC, United States

Abstract

Annually, millions of humans and animals suffer from chronic and acute pain, creating welfare and quality of life concerns for both humans and animals. There is a need to develop new and effective analgesic options as alternatives to opioids and non-steroidal anti-inflammatories (NSAIDs) for humans and animals. A major challenge in developing novel therapeutic approaches is accurately measuring the impact of pain in animal models in a way that is clinically relevant and predictive of clinical efficacy. The Pain in Animals Workshop (PAW) meetings are held every other year in partnership with the National Institutes of Health (NIH), bringing key stakeholders together to improve our understanding of the impact of pain in humans and animals and determine how best to measure this impact. The 2025 workshop explored the following topics: - Current perspectives on non-rodent models, - Artificial intelligence applied to the measurement of pain, - Evolutionary clues to pain mechanisms and novel measures, - Breed and sex differences in pain sensitivity (perceptions and reality). The workshop brought together academic, government, and industry experts. Under the topic of ‘Current perspectives on non-rodent models’, current views regarding such models were discussed, whilst also showcasing and discussing recent NIH funded/ongoing programs involving these models. With the current interest in non-rodent models and spontaneous disease models, the discussion on successes and challenges was timely. Given the topic's importance and the meeting's uniqueness, this narrative summarizes the presentations and discussions on the topic of current perspectives on spontaneous and other non-rodent disease models.

Introduction

There is a very high burden of chronic or persistent pain in humans, and thus a significant impact on individuals and society (1). Current treatments are limited and there is an ongoing need to develop new and effective analgesic options as alternatives to the current treatment options: opioids, that contribute to the opioid epidemic, and non-steroidal anti-inflammatories (NSAIDs), which can be associated with significant side effects. Despite exponentially increasing biomedical pain research (2), studies using current translational models are not resulting in enough effective novel therapeutics for chronic pain (3, 4). Indeed, it was recently stated that “despite generating a plethora of novel analgesic targets, pharmaceuticals for chronic pain treatment remain largely limited to the same 6 drug classes as present 40 years ago” (5). The failure of translational chronic pain research has been discussed with emphasis on the models and outcome measures in pre-clinical research (2, 6–10). The majority of preclinical models are induced (i.e., created) to model or mimic the target clinical conditions. While these models have increased our mechanistic understanding of pain conditions, they have not worked as well for selecting new analgesic drug candidates (5, 11). This has led to suggestions to utilize non-rodent models, including spontaneous disease models in non-rodent animals, to help inform pain therapeutic development. At the Pain in Animals Workshop (PAW) meeting in 2025, this topic (‘Current Perspectives: Non-Rodent Models’) was discussed. The 2-day Pain in Animals Workshop was held on September 26 and 27, 2025, at the National Institutes of Health campus, Bethesda, Maryland. The full agenda can be found in Supplementary File 1. This narrative is one product from that meeting, summarizing the presentations and discussions on the topic of ‘Current perspectives on non-rodent models’ from the workshop. This narrative is complementary to the recordings of these presentations and discussion at the workshop, which are archived at the NIH and are available at: Day 1, https://videocast.nih.gov/watch/d857b03d-d5db-11f0-9cf9-12c45c580ad9

Michele Sharkey PAW plenary lecture: cross-species insights into dorsal root ganglion biology: unraveling the mechanisms of pain

Dr. Ted Price gave the Michele Sharkey PAW Plenary lecture, describing and discussing his work with human tissues from patients suffering pain, and how such an approach could be extended to other species.

For decades pain researchers have mostly relied on rodent pain models to try to understand pain mechanisms and identify therapeutic targets for the treatment of pain in human patients. While this has led to important fundamental advances in our understanding of pain mechanisms, it has mostly not led to the identification of new targets that have been developed into new treatments for pain in the clinic. While there are many potential reasons for this, one glaring hole in our understanding of pain is our knowledge of the fundamental molecular features of the human pain pathway (12, 13). With advances in single cell and spatial transcriptomics, as well as progress in other areas like proteomics and increased access to precious human tissues, our understanding of the pain pathway is rapidly changing in many species, including in humans (14–20).

Dr. Price described what we now know about human pain sensing neurons in the peripheral nervous system, called nociceptors. The focus was on what we understand about how these cells change in people with neuropathic and other forms of chronic pain based on studies on human dorsal root ganglion tissues from rare surgeries where the dorsal root ganglia (DRG) is removed as part of the normal course of the surgery, or from DRG recovered from organ donors. Using single cell and spatial transcriptomics, as well as patch clamp electrophysiology, an emerging theme coming from these studies is that spontaneous action potential generation is frequently seen in neurons associated with neuropathic pain (21, 22). This effect may be driven by changes in voltage-gated sodium channels like Nav1.8 because selective inhibition with suzetrigine, blocks spontaneous activity (21), and because Nav1.8 mRNA expression is increased in these sensitized neurons as measured in patch-seq experiments (23). Another emerging area is the notion that neurodegeneration within the human dorsal root ganglia may play a key role in diabetic neuropathic pain. Recent observations of neuronal loss accompanied by the formation of Nageotte Nodules, small, neuroma-like structures first described by Jean Nageotte in the 1920's, are consistent with a link between neuronal degeneration and surviving neuron pathology that could drive pain in diabetic neuropathy (24). Interestingly, these Nageotte Nodules have been observed in the dorsal root ganglia in other species associated with viral sensory neuropathy (25, 26), and this was an area of discussion during the poster session at the PAW meeting.

As opposed to neuropathic pain where numerous neuronal transcriptomic changes are seen, it appears that non-neuronal cells show the biggest changes in dorsal root ganglia recovered from people with a history of chronic pain that does not have neuropathic qualities, suggesting that ongoing pain drivers within the ganglia originating in non-neuronal cell types might play an important role in non-neuropathic, persistent (chronic) pain (27). Such differences between different naturally occurring pain types are crucial to understand. Pain associated with arthritis is the most common cause of chronic pain affecting humans and other large mammals, including cats and dogs, and so future work should focus on understanding how dorsal root ganglia neurons change in mammals with naturally occurring painful arthritic diseases. This creates an enormous opportunity for collaboration between neuroscientists and veterinary medicine because the opportunity to procure tissues, such as dorsal root ganglia tissues, from subjects with arthritis pain is likely far greater in companion and production animals. Leveraging such an opportunity is likely to advance discovery of better targets for arthritic pain. With this opportunity in mind, Dr. Price discussed how our understanding of naturally occurring pain mechanisms in humans is, and is not, reflected in rodent models of pain and why there should be more research on understanding pain mechanisms using tissues obtained from veterinary chronic pain cases. These kinds of studies represent an excellent opportunity to understand how pain mechanisms are conserved across species, allowing researchers to focus on targets that can be assessed for clinical efficacy in veterinary medicine prior to, or in parallel with human pain trials.

The current role of non-rodent animal models in pain research

Dr. Julia Bachman provided an overview of the current perspective on non-rodent models, highlighting their advantages, but also the challenges, while emphasizing that the most appropriate model(s) will vary with the context of use, such as the stage of research and therapeutic development, and the pain state being investigated.

Understanding and treating pain requires research tools and approaches that reflect the complexity of biological systems, clinical syndromes, and patient variability. While rodent models remain essential for early discovery and mechanistic insights, non-rodent animal models, including those with naturally occurring pain, play a critical and increasingly recognized role in translational pain research. Dr Bachman provided an overview of the current state of non-rodent animal models in pain science, with a particular emphasis on companion animals experiencing spontaneous conditions as these models offer scientifically relevant platforms for evaluating analgesics –benefiting both veterinary and human medicine.

Non-rodent models add unique value, including improved alignment with human anatomy, physiology, and clinically relevant endpoints, as well as access to and the ability to employ advanced imaging, functional assessment tools, and non-pharmacological therapeutic approaches. However, there are challenges when using non-rodent models. These include the wide variability in pain expression both within and across different species – for example, the inherent differences between canine and ovine behavior related to one being a predator species (that has the luxury to be more demonstrative in response to pain), and the other a prey species (behavioral responses to pain are muted, or ‘hidden’). With multiple species being considered, this multiplies the required work to develop validated outcome measures in each species. Just as it applies to rodent models, context-appropriate model selection is important, which requires a deep understanding of species-specific behavior, and even understanding behavioral differences within a species. Dr Bachman prompted researchers to consider what it means for a model or measure to be validated, noting the varied terminology and types of validity, and highlighted issues that arise when trying to validate models and outcome measures in parallel.

Recommendations from recent strategic planning efforts conducted as part of the NIH's Helping End Addiction Long-term® Initiative (the NIH HEAL Initiative®) include the development of a new generation of highly predictive disease-specific animal and cellular models (28), while ongoing efforts focused on discovery research in human pain biology create enormous opportunity for “back translation” of these findings to models used for both basic and translational research. Emerging methodologies—such as organ-on-chip systems, human-derived nociceptors, and in silico models are also important ‘non-rodent’ model systems that can complement and cross-inform traditional approaches, as they can enhance study design and reduce reliance on rodent and other research animal models where appropriate.

Recognizing that no single model fits all purposes, there is a need for multidisciplinary expertise in choosing and implementing the appropriate animal model(s) for pain research. Input from veterinarians, clinicians and pain researchers, behaviorists, statisticians, and regulatory scientists is essential to ensure rigor and scientific relevance. By leveraging diverse models, scientific expertise, and collaborative frameworks, the field can make meaningful progress toward understanding and alleviating pain in all species.

A comparative approach to the leaky gut and osteoarthritis

Dr. Amanda Nelson is the project leader for an NIH funded study involving humans and pet dogs: Is the gut important in multiple joint osteoarthritis? A multimodal investigation in humans and pet dogs (https://www.med.unc.edu/medicine/rheumatology-allergy-immunology/people/amanda-e-nelson-md-mscr/). She provided an overview of the project, the rationale for concurrently using pet dogs and humans, and discussed early results demonstrating the fidelity between multijoint OA (MJOA) in the two species.

Osteoarthritis is the most common form of arthritis in both humans and pet dogs and frequently involves multiple joint sites. Multiple joint osteoarthritis suffers from a lack of standard classification criteria in both humans and pet dogs, but is widely recognized clinically and is suggestive of a more systemic process (29). Intestinal permeability and microbial dysbiosis contribute to low-grade systemic inflammation in a variety of conditions commonly comorbid with OA (e.g., diabetes, obesity) (30), leading us to explore a potential role for these factors in MJOA. The shared frequency and contributing factors in both humans and pet dogs suggest that pet dogs provide a relatively untapped model of disease with shorter time to progression (31) and potential to develop therapeutics for both humans and dogs.

The study was designed as a parallel prospective community-based cohort study in humans and in pet dogs (NIAMS R01AR080733) to investigate the frequency and risk factors for MJOA, with a focus on intestinal permeability and the microbiome as contributors to low grade systemic inflammation (initial results have been published 32).

Human participants were recruited from the community-based Johnston County Health Study (JoCoHS, PI: Nelson 33), along with an independent cohort of pet dogs recruited to NC State College of Veterinary Medicine (PI: Lascelles). Questionnaires, functional assessments, standardized multiple joint radiographs and pain assessments, blood and fecal samples were obtained in all participants (human and dog). In the canine population, validated owner (proxy) questionnaires and veterinarian pain assessments, as well as objective measures of activity, sensitivity and limb use were employed to match the human assessments, as recently communicated (32). Microbiome analysis was done by 16S rRNA amplicon sequencing. MJOA was defined as ≥3 unique joint sites (bilateral joint=1 site) involved; symptom burden was based on validated self-reported/proxy measures of pain. Intestinal permeability was directly assessed using sugar-based assays: a lactulose:mannitol dual sugar test in humans, and an iohexol-based absorption test in dogs. Descriptive statistics and Spearman correlations with Benjamini-Hochberg correction for multiple testing were used to determine relationships among lab tests, pain, intestinal permeability, and microbiome diversity measures.

Human participants (n = 100, 63% women, mean age 56 years, mean body mass index 34 kg/m2) and pet dogs (n = 115, 40% spayed females, 57% neutered males, mean age 8 years, mean weight 27 kg) were included in preliminary analyses. A nearly identical proportion, 20% in each cohort, had radiographic MJOA. The most common sites in humans were knees, hands and feet, while in dogs the hips were most frequently affected followed by shoulder and elbow. Several members of each cohort had OA in more than 4 sites, reflecting a high OA burden. Clinical lab assessments (e.g., blood counts, liver function, glucose) were generally unremarkable, and similar in the human and dog cohorts. The frequency of directly assessed intestinal permeability was low in both cohorts regardless of MJOA status.

Microbial α-diversity did not differ statistically between participants with or without MJOA, although a few taxa were differentially abundant by MJOA status. Additionally, lower levels of genera Christensenellaceae and Lachnoclostridium in humans, and butyrate-producing Faecalibacterium in dogs, were correlated with greater pain severity, as were higher levels of Escherichia-Shigella in dogs and were statistically significant.

In this unique, parallel, community-based study of naturally occurring MJOA in humans and pet dogs, early results identified similar patterns of radiographic and symptomatic multiple joint involvement in both cohorts, supporting the use of dogs to model naturally occurring MJOA. Taxa potentially related to radiographic MJOA and pain were identified in this preliminary analysis, providing new insights into links between dysbiosis and MJOA. The logistically cumbersome ‘gold standard’ tests for intestinal permeability did not demonstrate strong associations with MJOA (34), and controversy regarding the best method for assessment persists. Future planned work in this project will incorporate additional assessments (e.g., circulating biomarkers, cytokines, indirect measures of intestinal permeability) as well as longitudinal assessments in both the human and canine cohort to further understand these relationships.

Overall, our work so far suggests high fidelity between human and dog MJOA burden, and other health characteristics, supporting further work in the dog model of naturally occurring MJOA, including testing interventions. Such ‘trials’ would result in more rapid readouts than similar trials in humans.

Cross-species validation of B cell-mediated neuropathic pain: From rodents to pigs and beyond

Dr. Peter Grace leads an NIH funded study involving murine and piglet models: Regulation of peripheral neuropathic pain by B-cells (https://reporter.nih.gov/search/Pubv45yjkkK6VSMkjG8sBw/project-details/10798311). He provided an overview of the project, describing the results found in the mouse model, and then described the validation work in a piglet model – a model that reflects real-world husbandry approaches in piglets. The rationale for incorporating the piglet model was also discussed.

Pain arising from a lesion or disease of the somatosensory system—neuropathic pain—remains refractory to current analgesics (35). Neuroimmune interactions have emerged as central to initiation and persistence of this pain (36, 37) Recent work from our group has shown that peripheral nerve injury leads to activation and differentiation of B cells, potentially due to the de novo expression of autoantigens (38–42). Secreted IgG forms immune complexes with de novo antigenic epitopes expressed after nerve injury to activate Fcγ receptor (FcγR)-expressing cells in dorsal root ganglia (DRG) and the spinal cord, which leads to neuronal hyperexcitability and mechanical allodynia (38–42). However, this mechanistic work was performed in mice, with human DRG sections confirming IgG accumulation (38–42).

Recent, unpublished work is revealing that peripheral nerve injury induces clustering of B cells, follicular helper T cells, dendritic cells, and stromal cells into clusters in the DRG meninges that resemble tertiary lymphoid structures, including high endothelial venules and lymphatic elements. These structures have potential to promote ongoing germinal center–like activity and class-switched IgG production in close proximity to sensory neuron somata, amplifying neuroimmune crosstalk that maintains neuropathic pain.​

To determine whether these processes may be conserved in higher species, we investigated routine tail docking in a non-rodent model - piglets - as a model of traumatic nerve injury and potential chronic neuropathic pain. Tail docking was performed within the first week of life and resulted in neuroma formation at the stump for at least 12 weeks, with prior work demonstrating long-lasting mechanical sensitization, altered gait, and changes in posture and feeding behavior consistent with ongoing pain (43–45). Porcine and human immune systems share substantially greater similarity than mouse and human, enhancing the translational relevance of immune mechanisms identified in this model (46).

In tail-docked piglets, DRG harvested 42 days post-procedure showed marked IgG immunoreactivity compared with sham-operated littermates, indicating deposition of IgG within caudal ganglia that parallels findings in mouse lumbar DRG after nerve injury. B cells and macrophages cluster within the connective tissue surrounding piglet DRG cell bodies, echoing the tertiary lymphoid–like architecture observed in mouse DRG meninges and suggesting that local germinal center–like activity and FcγR-bearing myeloid effectors are also engaged in the porcine system. A comprehensive longitudinal protocol is underway that aligns behavior and biochemical assessments with these observations.

Collectively, these cross-species data support the B cell–IgG response as a conserved immune response to traumatic nerve injury, and likely relevant to human pain conditions. Establishing pain-related behavioral correlates in the piglet model will enable rigorous evaluation of B cell–targeted and FcγR-modifying therapeutics in a large animal with immune features closer to humans, addressing current gaps in the translation of neuroimmune pain mechanisms. This work ultimately aims to validate B cell–directed strategies as a novel class of analgesics for neuropathic pain patients who currently lack effective, mechanism-based treatments.

Canine biopsychosocial model of osteoarthritis

Dr. Margaret Gruen is the project leader for an NIH funded study involving pet dogs: Innovative modeling of the biopsychosocial model in animals: Validation of outcomes for assessing emotional and cognitive domains affected by naturally occurring chronic pain in dogs (https://reporter.nih.gov/search/ZSw6VjMHP0GnqF9GaBjvtQ/project-details/11050788). She discussed the need for comprehensive measures of emotion and cognition in animal models and provided the rationale for developing these measures in the spontaneous pet dog model of OA pain.

Chronic pain conditions remain a major public health burden, with OA the leading cause of persistent pain and disability. In the United States, painful OA affects nearly 90 million adults, profoundly impairing quality of life and contributing to anxiety, depression, pain catastrophizing, and cognitive dysfunction (47–52). These psychological dimensions are central to the chronic pain experience, yet they are poorly represented in most existing preclinical models. Dogs with naturally occurring OA pain offer an opportunity to address this gap. Canine OA closely parallels human disease in pathology, chronicity, and functional impact, including gait abnormalities, sleep disturbances, reduced activity, and owner-reported impairments (53–55). Importantly, dogs display relevant emotional (56) and cognitive processes (57, 58) and live in shared environments with humans, making them uniquely suited to model the biopsychosocial complexity of chronic pain.

To address the need for comprehensive measures of emotion and cognition that are relevant to pain in dogs, our group has developed a set of assessments (the Dog Pain-Related Emotion and Cognition Test Battery, DECTB-P) that will allow evaluation of these domains. The first phase of this study focused on construction and refinement of the DECTB-P, integrating validated assays of affect (anxiety, depression-like behavior, catastrophizing) (59) and cognition (working memory, attention, inhibitory control, judgment bias) (57) with owner-reported assessments (Client-reported outcome measures). Novel measures, such as spatial discounting and anhedonia assessments, have been developed to expand evaluation of pain-related domains. Spatial discounting is a task used to measure emotional decision making, where the distance to a larger food reward is increased sequentially, and the distance at which a dog ’switches’ to retrieve a closer, smaller treat is recorded. Anhedonia, or loss of enjoyment in pleasurable activities, is assessed through evaluation of a dog's willingness to engage with their owner and with a food-delivery device. Spontaneous measures of dogs’ responses to enjoyable activities in the home are also being collected. Tasks have been optimized for feasibility, efficiency, and minimal redundancy (Table 1).

Table 1

CategoryDomain affected in humansTest in dogs
Emotion/AffectAnxietySurprising event/Attention bias (PM)
CBARQ, Lincoln Sound Sensitivity Scale (CROMs)
DepressionAnhedonia (PM)
Exercise and greeting response (PM)
Canine owner reported quality of life scale (CORQ)
Pain catastrophizingConditioned heat paradigm (PM)
Cognitive functionExecutive functionAttention/attentional interferenceSpatial working memory with distraction (PM)
Working memorySustained attention (PM)
Holeboard test of spatial working memory and reversal (PM)
Inhibitory controlCylinder & detour (PM)
Emotional decision makingJudgement bias (PM)
Spatial discounting (PM)
General cognitionUnsolvable task (PM)
CAnine DEmentia Scale (CADES) (CROM)

Tasks included in the Dog Pain-Related Emotion and Cognition Test Battery (DECTB-P).

Canine battery elements are based on the domains assessed and relevance to affected domains in humans with chronic pain. PM, performance measure; CROM, client reported outcome measure; CBARQ, Canine Behavioral and Research Questionnaire.

Using the DECTB-P, the next phase of the study will evaluate the battery's validity and responsiveness. In a cohort of dogs with and without OA pain, we will assess discriminative validity, test–retest reliability, and structural validity, benchmarking against gold-standard pain measures including the Canine Brief Pain Inventory, gait asymmetry, and accelerometry (53, 60, 61). Responsiveness of the battery will be tested through a blinded, randomized, placebo-controlled longitudinal analgesic trial in dogs with OA. Advanced statistical modeling, including factor analysis and item response theory, will refine the DECTB-P into a concise, clinically practical tool. Finally, videos and protocols will be developed that will allow other pain researchers to incorporate these measures into their studies, improving the translational relevance of the spontaneous OA pain model in dogs. These videos and protocols will also allow assessment of these domains in clinical canine patients and expand the cross-species comparative applications of this work.

Through development of the DECTB-P, this work will produce the first validated, naturally occurring animal model of chronic pain incorporating measurable biological and psychological outcomes. Ultimately, the canine OA model with integrated emotional and cognitive measures will accelerate development of effective non-opioid therapies and advance mechanistic understanding of chronic pain. The current work and the DECTB-P covers psychological domains; in the current work, social factors that may influence pain are not directly measured. Candidate social factors include the caregiver, caregiver-dog relationship, other pets, and housing and environment. Owner-reported measures of function and cognition/affect likely capture some of this indirectly. Future work should address the ’social’ factors to move the model towards a full ‘biopsychosocial’ model of the pain experience.

Discussion

Presentations focused on the use of non-rodent models in chronic pain translational research. Several interrelated themes (Box 1) emerged from the discussion following the presentations: the (mis)use of the term ‘validation’ in pain research, the challenges of cross-species translation, the role of different animal models, and the importance of integrating biological, behavioral, and environmental complexity when studying pain.

BOX 1

Summary of the main discussion points.

  • Misuse of “Validation” in Pain Research

  • Challenges of Cross-Species Translation

  • Comparative Value of Different Animal Models

  • Induced vs. Naturally Occurring Disease Models

  • Multidimensional Nature of Pain

  • Cognitive and Affective Dimensions of Pain

  • Fundamental yet Variable Nature of Pain Across Species

A central concern was the field's reliance on the term ‘validated’. Participants argued that the concept is often misused as a binary label, with reference to something being either validated or not, when in reality it reflects a continuum of evidence. All measures, models, and tools exist along a spectrum of support, contingent on context, population, and application. Treating validation as a definitive endpoint risks stagnation. It was cautioned that once a tool is labeled ‘validated’, it may be used inappropriately, and without appropriate critique, outside the conditions under which it was originally assessed. This is of particular concern in translational pain science, where instruments may not generalize across species, conditions, or different formats of use. Rather than abandoning the term entirely, there was discussion that more specific and precise language should be used when referring to an instrument as validated - specifying what has been validated, in what context, and under what circumstances - and for recognizing validation as an ongoing, iterative process.

The translational research process of moving from rodent models to larger animals and then to humans was also discussed, with participants noting increasing uncertainty in tools (e.g., antibodies), gene annotations, and other biological aspects at each step. Advances in genomics and proteomics were viewed as powerful solutions, enabling the application of unbiased, system-level comparisons across species. While technical limitations, such as incomplete genome annotation in non-rodent, non-human species, still exist, these were framed as solvable problems rather than fundamental barriers. Importantly, some translational difficulties stem not from species differences per se, but from the lack of effective therapeutics (known positives) to serve as appropriate benchmarks. Without access to a known effective therapeutic, it becomes difficult to assess whether a model or measure is truly predictive. In this context, it was noted that highly efficacious treatments, could be viewed as valuable tools in the process of validation of models and outcome measures.

A substantial portion of the discussion focused on the comparative value of different animal models. There was broad agreement that no single species offers a perfect representation of human pain, and that overemphasizing similarities or differences between any one species and humans can be misleading. The common assumption that larger mammals such as pigs or dogs are inherently more human-like than rodents was challenged; all species exhibit meaningful biological differences, and in some domains, it was argued, mice may be as close, or closer, to humans as other mammals. The unique strengths of each species were nonetheless acknowledged. Rodents provide unparalleled genetic tools and mechanistic insights that have been foundational for understanding nociception and neural circuitry, while larger animals, including companion dogs, offer advantages in modeling naturally occurring disease, shared environments, similar comorbidities, comparable psychosocial overlays and complex behaviors.

This led to a consensus view: pain research benefits from a pluralistic approach that leverages multiple species, each selected based on the specific question being asked. Pain is not a unitary phenomenon; conditions such as osteoarthritis, fibromyalgia, and headache differ substantially in their underlying mechanisms and clinical experience - and different models may therefore be appropriate for different pain states. Rather than seeking a single best model, the field should focus on aligning models with the biological and clinical features of interest.

The discussion also highlighted the distinction between induced experimental models and naturally occurring disease. There was strong support for studying animals with spontaneous conditions — such as osteoarthritis in dogs or lameness in livestock — as these may better capture the complexity and chronicity of human pain. Companion animals, in particular, were seen as valuable because they share environments, diets, and even microbiomes with their owners. This shared context may enhance translational relevance, especially for systemic or multifactorial conditions, though participants cautioned against oversimplifying these comparisons and emphasized the need for careful characterization of both similarities and differences.

Another key theme was the multidimensional nature of pain, particularly the integration of sensory, emotional, and cognitive components. While significant progress has been made in understanding peripheral and spinal mechanisms — largely through rodent research — major gaps remain in our understanding of higher-order central processing. Brain imaging tools in humans provide some insight but lack the cellular resolution needed to uncover underlying mechanisms, underscoring the continued importance of animal models with advanced experimental capabilities.

There was also discussion of emerging efforts to study cognitive and affective dimensions of pain in animals, including constructs analogous to catastrophizing. Although still in early stages, there is growing interest in developing behavioral paradigms to capture these aspects in species such as dogs. These approaches may ultimately complement traditional outcome measures such as mobility assessments, providing a more comprehensive picture of pain and its modulation. Challenges in translating such constructs were acknowledged, particularly given differences in communication and cognition across species. Strategies drawn from pediatric or caregiver-based frameworks were suggested as potential analogies.

Finally, the group addressed questions about the fundamental nature of pain across species, including whether brain size or neuron number correlates with pain experience. The consensus was that such comparisons are overly simplistic. The organization and connectivity of neural systems (particularly how nociceptive signals engage distributed brain networks) are likely more relevant than gross anatomical metrics. Across mammals, these systems appear to function as alarm or warning networks, suggesting some shared features of acute pain experience. Chronic pain, however, is likely more variable, shaped by species-specific biology, behavior, and ecological context.

In summary, the discussion underscored the complexity of pain research and the need for nuanced, context-dependent approaches to animal modeling. Key points included the importance of moving beyond binary notions of validation; embracing multiple species and models tailored to specific questions; leveraging advances in molecular and systems biology for cross-species comparison; and expanding outcome measurement to include cognitive and affective dimensions. Together, these perspectives point toward a more integrated and flexible framework for advancing translational pain science.

Statements

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Author contributions

TP: Writing – original draft, Writing – review & editing. JB: Writing – original draft, Writing – review & editing. AN: Writing – original draft, Writing – review & editing. PG: Writing – original draft, Writing – review & editing. MG: Writing – original draft, Writing – review & editing. DB: Writing – original draft, Writing – review & editing. JC: Writing – original draft, Writing – review & editing. MG: Writing – original draft, Writing – review & editing. CJ: Writing – original draft, Writing – review & editing. MO: Writing – original draft, Writing – review & editing. SR: Writing – original draft, Writing – review & editing. ES: Writing – original draft, Writing – review & editing. BL: Conceptualization, Data curation, Writing – original draft, Writing – review & editing.

Funding

The author(s) declared that financial support was received for this work and/or its publication. The PAW 2025 meeting was supported by The Mayday Fund through a grant (PAM-P25-001850) to NC State University College of Veterinary Medicine (PI: BL). Additional support was provided by the NC State College of Veterinary Medicine Comparative Pain Research and Education Center.

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author BL declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpain.2026.1999875/full#supplementary-material

References

Summary

Keywords

measurement, non-rodent models, pain, pain in animals workshop, translational

Citation

Price T, Bachman JL, Nelson AE, Grace PM, Gruen ME, Brown DC, Coetzee JF, Gill M, Johnson C, Oshinsky ML, Robertson SA, Smith ER and Lascelles BDX (2026) Current perspectives: non-rodent models of pain: Pain in Animals Workshop 2025. Front. Pain Res. 7:1999875. doi: 10.3389/fpain.2026.1999875

Received

15 September 2026

Revised

16 October 2026

Accepted

16 October 2026

Published

11 November 2026

Volume

7 - 2026

Edited by

Nick Andrews, Salk Institute for Biological Studies, United States

Reviewed by

Stephan Leisengang, University of Giessen, Germany

Lorena Garcia Menendez, Scripps Research, United States

Updates

Copyright

*Correspondence: B. D. X. Lascelles

† These authors have contributed equally to this work and share first authorship

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics